Myxoid/round cell (RC) liposarcomas (MLS) were originally classified into two distinct populations based on histological differences; a myxoid component and a RC component. It is notable that, depending on an increase of the RC component, the prognosis significantly differs. Hence, the RC component is associated with metastasis and poor prognosis. However, the molecular mechanisms that contribute to the malignancy of the RC component still remain largely unknown. Here, we report microRNA-135b (miR-135b), a key regulator of the malignancy, highly expressed in the RC component and promoting MLS cell invasion in vitro and metastasis in vivo through the direct suppression of thrombospondin 2 (THBS2). Decreased THBS2 expression by miR-135b increases the total amount of matrix metalloproteinase 2 (MMP2) and influences cellular density and an extracellular matrix structure, thereby resulting in morphological change in tumor. The expression levels of miR-135b and THBS2 significantly correlated with a poor prognosis in MLS patients. Overall, our study reveals that the miR-135b/THBS2/MMP2 axis is tightly related to MLS pathophysiology and has an important clinical implication. This work provides noteworthy evidence for overcoming metastasis and improving patient outcomes, and sheds light on miR-135b and THBS2 as novel molecular targets for diagnosis and therapy in MLS.
INTRODUCTION
Liposarcoma (LPS) is one of the most common soft tissue sarcomas in adults, and it is classified into three subtypes according to histopathological examination: well-differentiated/ dedifferentiated LPS, myxoid/round cell (RC) LPS (MLS) and pleomorphic LPS. MLS accounts for 30-35% of all LPS cases and approximately 10-15% of all adult soft tissue sarcomas. 1 MLS covers a wide morphological spectrum of tumors ranging from pure myxoid tumors to hypercellular RC tumors. MLS with a more than 5% RC component is associated with poor prognosis and metastasis, 2, 3 and patients with this type of MLS typically receive combined chemotherapy and radiotherapy. The 5-year survival rate is significantly lower for MLS patients with a more than 5% RC component (40-60%) compared with MLS patients with a less than 5% RC component (70-90%). [4] [5] [6] The characterization of the RC component using hematoxylin and eosin staining and the RC ratio remains the gold standard for predicting MLS prognosis. However, it can be difficult to determine an accurate percentage of the RC component because of sampling bias, especially with small biopsy specimens, 7 and ambiguous boundaries. 8 Therefore, further investigations into the mechanisms that contribute to the malignancy of the RC component and the identification of new diagnostic markers are required to improve the reliability in predicting MLS patient outcomes. microRNAs (miRNAs) are small non-coding RNAs of approximately 22 nucleotides that are related to various biological processes such as development, differentiation, apoptosis and proliferation. 9 The abnormal expression of miRNAs has been observed in solid and hematopoietic tumors, resulting in tumor initiation and progression. 9, 10 In MLS, suppression of miR-486 by TLS-CHOP, a fusion transcript resulting from the 12q13 and 16p11 translocations in o95% of MLS patients, increases the expression of plasminogen activator inhibitor-1, thereby enhancing cell growth. 11 In a copy number variation study, miR-26a-2 has been found to be amplified and highly expressed in 22 MLS patients and affects cell proliferation and survival by inhibiting a regulator of chromosome condensation and BTB domain containing protein 1. 12 Global miRNA expression analyses using microarrays from high-grade soft tissue sarcomas 13 and various subtypes of LPS 14 have enabled the identification and classification of MLS tumors based on their miRNA expression profiles.
Despite evidence of miRNA deregulation in MLS, little is known regarding the contribution of miRNAs in the RC component malignancy and the molecular and clinical implications of miRNAs in MLS. Here, we report that miR-135b is highly expressed in the RC component and promotes invasion in vitro and metastasis in vivo. Moreover, miR-135b triggers histopathological abnormalities via an enhanced degradation of the extracellular matrix by the increased matrix metalloproteinase 2 (MMP2) through the direct downregulation of thrombospondin 2 (THBS2). Finally, we show statistical significance and clinical relevance of miR-135b and THBS2, which correlated with a poor prognosis in MLS. Our findings demonstrate a critical pathway involving miR-135b and THBS2 that could represent a valuable prognostic biomarker and therapeutic target for MLS patients.
RESULTS

miR-135b overexpression in the RC component is associated with MLS cell invasion in vitro
To identify the miRNAs responsible for malignancy of the RC component in MLS, we performed laser-capture microdissectionbased miRNA microarray analyses of the myxoid and RC components ( Figure 1a ). Eight formalin-fixed, paraffin-embedded (FFPE) samples from seven MLS patients who never received chemotherapy or radiotherapy (six primary tissues and one recurrent tissue) contained sections with a more than 5% RC component. On the basis of the array analysis, 16 candidate miRNAs were identified as exhibiting significantly high expression in the RC component (Figure 1b) . Eleven out of 16 miRNAs were validated by qRT-PCR, and we focused on miR-135b because it displayed the highest upregulation in the RC component ( Figure 1c and Supplementary Figure 1) . miR-135b expression was significantly higher in three MLS cell lines compared with adipose tissue-derived mesenchymal stem cells (Figure 1d ) and also higher in MLS patient tumor tissues (regardless of the cellular component, n = 30) compared with adjacent normal tissues (n = 25) (Figure 1e) . Notably, the increased miR-135b levels correlated with the RC ratio ( Figure 1f ). As the RC component is considered as a key factor in cancer invasion, we tested miR-135b effect in cell invasiveness in vitro. First, we performed a serial cell invasion assay using a Matrigel invasion chamber ( Figure 1g ) and obtained highly invasive clones (Supplementary Figure 2a) , which overexpressed miR-135b compared with parental cells (Figure 1g ). Next, we transiently transfected the 2645-94 and 402-91 cell lines with the miR-135b mimics. It significantly promoted the invasive ability of both MLS cell lines (Figure 1h and Supplementary Figures 2b-d) . However, increased miR-135b expression did not affect cell growth (Supplementary Figure 2e) or migratory activity (data not shown). These results suggest that miR-135b is an oncogenic miRNA highly expressed in the RC component and has a critical role in MLS cell invasion.
THBS2 is a direct target of miR-135b in MLS To identify the target of miR-135b, we integrated expression data of genes and miRNA with in silico approaches (five target prediction algorithms). Four genes were isolated as miR-135b targets on satisfying three of the following conditions (Figure 2a ). Genes that were (i) downregulated in the RC component by 1.5-fold compared with the myxoid component in the mRNA sequencing of the total RNA derived from the clinical FFPE samples; (ii) downregulated in miR-135b-overexpressing cells by fivefold compared with the negative control (NC) in the mRNA microarray of the 2645-94 cells; and (iii) predicted as targets of miR-135b using in silico analysis. THBS2, interleukin 1 receptor 1 (IL1R1), glutamate receptor, ionotropic, AMPA 3 (GRIA3), and collagen, type V, alpha 1 (COL5A1) were selected as final candidate targets for miR-135b. To test them, miR-135b was transiently overexpressed in MLS cells, and the expression levels of the four genes were quantified by qRT-PCR. Only THBS2 and IL1R1 expressions were significantly decreased in miR-135b-overexpressing cells (Figure 2b ). The expression level of THBS2 in all three MLS cell lines was significantly lower than in adipose tissue-derived mesenchymal stem cells, but that of IL1R1 was not (Figure 2c and Supplementary Figure 3a) . Protein level of THBS2 in all three MLS cell lines was lower than in adipose tissuederived mesenchymal stem cells (Supplementary Figure 3b) and also clearly decreased after transient transfection with the miR-135b mimics (Figure 2d and Supplementary Figure 3c) . To further verify whether THBS2 is a direct target of miR-135b, we performed a 3′ UTR assay. The luciferase activity level was significantly reduced by approximately 40% in the cells cotransfected with the miR-135b mimics compared with the NC. In contrast, the cotransfection with the mutated form of 3′ UTR resulted in no significant change in luciferase activity (Figure 2e ). Taken together, our data strongly indicate that THBS2 is a direct target of miR-135b in MLS.
Inverse correlation between miR-135b and THBS2 in MLS We next looked at the expression levels of THBS2 in clinical samples of MLS by qRT-PCR with the FFPE samples of the myxoid and RC components. We found that THBS2 expression was lower in the RC component compared with the myxoid component in six of the eight samples (Supplementary Figure 4a) . Likewise, a decreased expression level of THBS2 was confirmed by immunohistochemistry in the RC component compared with the myxoid component in the clinical MLS FFPE samples (Figure 3a) . It was further confirmed in a tissue microarray containing nine myxoid LPS tissues (positivity: six out of nine, 67%) and three RC LPS tissues (positivity: one out of three, 33%) (Figure 3b and Supplementary Figure 4b) . We then scrutinized the expression levels of THBS2 in MLS patient tumors. THBS2 expression was significantly decreased in tumors (Figure 3c ) and tended to be inversely correlated with miR-135b depending on the RC ratio (Figure 3d miR-135b increases the total amount of MMP2 in extracellular environments by repressing THBS2 expression To confirm the association between miR-135b and MLS progression, we performed a pathway analysis from the mRNA sequencing comparing the myxoid and RC components. Ten pathways (nine upregulated and one downregulated in the RC component) were identified as significant with an FCo − 2.0 (Figure 4a ). We looked into the pathway of matrix metalloproteinases, which are involved in invasion and metastasis. We focused on the MMP2 of them all, one of the genes in the pathway 'matrix metalloproteinases' because previous studies have demonstrated the interaction between THBS2 and MMP2. [15] [16] [17] Therefore, we first determined the expression levels of MMP2 in clinical frozen tissue samples. MMP2 expression was significantly higher in MLS tumors than in adjacent normal tissues in frozen tissue specimens (Figure 4b and Supplementary Figure 7a) and also exhibited the higher protein existence in the RC component than in the myxoid component (Supplementary Figure 7b) . So, we conducted a gelatin zymography assay with the cell conditioned media as described in Figure 4c , to evaluate the existence of pro-and active-MMP2 after transient transfection with the miR-135b mimics, the THBS2 siRNAs and the NC. When treated with the conditioned media derived from the miR-135b mimic-transfected cells, the amount of both pro-and active-MMP2 was enhanced as well as the THBS2 siRNAs ( Figure 4d and Supplementary Figure 8) . Collectively, our data demonstrate that miR-135b induced the accumulation of total MMP2 through the downregulation THBS2, leading to increased invasiveness in MLS.
miR-135b enhances tumor enlargement and triggers histopathological abnormality in tumors in vivo To examine the effects of miR-135b on tumor enlargement and histopathological changes in vivo, we set up a MLS xenograft model using intramuscular injections into NOG mice. For tumor growth monitoring, we established 2645-94 cell lines stably expressing miR-135b or control miRNA with the pLV-GFP-Luc plasmid DNA as 
Silencing of miR-135b inhibits the development of lung metastasis in established high lung-metastatic MLS cells in vivo
To evaluate the effect of miR-135b on metastasis in vivo, we established high lung-metastatic 2645-94 cells, named 2645-94 GFP-Luc LM2 (LM2) (Figure 6a ). These cells were characterized by rapid and high lung metastasis frequencies (Table 1) and increased tumorigenic ability in vivo (Supplementary Figures 10a and b) . The invasion values were normalized to those of the control; n = 4 per group. Student's t test was used for statistical analyses. All data are presented as the mean ± s.e.m. *P o0.05; ***P o0.01.
Clinical relevance of high expression of miR-135b and low expression of THBS2 linking to poor prognosis in MLS Given that the RC component in MLS is a risk factor associated with poor prognosis, miR-135b and THBS2 expression levels also could be critical factors to predict prognosis in MLS. To this end, we examined the survival outcomes of 64 MLS patients (Supplementary Table I ). A Kaplan-Meier analysis revealed that the presence of a more than 5% RC component closely correlated with poor prognoses in MLS patients (log-rank test, P = 0.001 for disease-free survival, Figure 7a ). Next, we examined the correlation between MLS patient outcomes and the expression levels of miR-135b and THBS2 in clinical FFPE biopsy samples. Kaplan-Meier analyses indicated that high expression levels of miR-135b and low expression levels of THBS2 were significantly associated with poor prognoses (logrank test, P = 0.006 and 0.001 for disease-free survival, respectively, Figures 7b and c) . Consequently, the miR-135b and THBS2 expression levels appeared to be more relevant than the ratio of the RC component in predicting clinical outcomes (log-rank test, P = 0.016 for disease-free survival, Figure 7d ). These data strongly suggest that miR-135b and THBS2 could be valuable prognostic biomarkers reflecting the clinical behaviors of MLS tumors.
DISCUSSION
In previous research, MLS cases were initially categorized as either myxoid LPS or RC LPS. However, because both myxoid and RC 
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LPSs were observed on the same morphological continuum and contained the same the 12q13 and 16p11 translocations (resulting in the TLS-CHOP fusion transcript), the two types of sarcomas have been grouped together as myxoid and RC LPS. 18 More than 95% of MLS patients have the TLS-CHOP fusion transcript; TLS-CHOP is a key molecule associated with tumor initiation and the inhibition of adipogenesis. 19, 20 However, the RC component is also a risk factor associated with metastasis and poor prognosis. Thus, the presence of TLS-CHOP in MLS patients cannot fully account for the malignancy or the morphological spectrum. There are several reports concerning the relationship between the myxoid and RC components. Some groups have reported that the myxoid and RC components are the well-differentiated and the poorly differentiated MLS populations, respectively. 21, 22 In other studies, further genetic damage, 23 PI3K/Akt pathway activation 24 and heparin-binding EGF-like growth factor secretion by tumor-associated macrophages 25 following MLS initiation by TLS-CHOP were suggested as factors leading to the transformation from the myxoid to the RC component. However, many of the details regarding the relationship between the two components are unknown. We hypothesized that overexpressed miRNAs in the RC component may contribute to tumor progression and the histopathological differences from the myxoid component. In this study, we found that miR-135b was more highly expressed in the RC component and was associated with cell invasion in vitro and metastasis in vivo. To the best of our knowledge, this is the first report to compare the miRNA profiles of the myxoid and RC components and to investigate in detail the effect of miRNA in MLS progression. Previous studies have reported that miR-135b is dysregulated in colorectal cancer, [26] [27] [28] [29] lung cancer, 30 pancreatic cancer, 31 liver cancer 32 and osteosarcoma, 33 indicating that miR-135b generally functions as an oncogenic miRNA. Lin et al. 30 have reported that miR-135b promotes tumor growth, cellular invasiveness and metastasis in lung cancer by repressing multiple key components of the Hippo pathway network with the tumor suppressor LZTS1. Li and colleagues 32 have demonstrated that miR-135b promotes tumor invasion and metastasis by regulating RECK and EVI5 in hepatocellular carcinoma. In agreement with these reports, we found that miR-135b was involved in promoting MLS cell invasion and metastasis.
We further demonstrated that miR-135b increased the total amount of MMP2 in the extracellular matrix through the direct suppression of THBS2. Previous studies have reported that low expression levels of THBS2 are associated with poor prognoses in gastric cancer, 34 prostate cancer, 35 colon cancer 36 and pancreatic cancer. 37 Moreover, THBS2 contributes to cancer progression, such as invasion 37 and metastasis. 38 In the current study, patient sample no. 3 of FFPE displayed a high expression level of THBS2 in the RC component despite the high miR-135b expression. We considered that this contradictory expression between miR-135b and THBS2 might be due to polymorphisms, such as single nucleotide mutations and insertion/deletions, at miRNA target sites.
39-41 However, we obtained consistent expression patterns between miR-135b and THBS2 in almost all clinical samples and our in vitro experiments strengthened the inverse correlation. Moreover, THBS2 binds to both pro-MMP2 and active-MMP2 with high affinity. Then, this complex is cleared from the pericellular environment by binding with the low-density lipoprotein receptor-related protein receptor and directed to the lysosomes for degradation. This mechanism has an important role in the regulation of extracellular MMP2 levels. [15] [16] [17] Previous studies have 42 However, MT1-MMP expression did not change between the myxoid and RC components in our study. Consequently, our data suggest that a molecular mechanism independent of MT1-MMP based on the regulation of THBS2 expression by miR-135b enhances the accumulation of total MMP2 in the extracellular environment, leading to cell invasion and metastasis in MLS.
From the results of the animal experiments, we found that miR-135b overexpression triggered histopathological changes as evidenced by increased cellular densities and decreased extracellular collagen matrix. These histopathological findings were similar to the RC component observation in human MLS. Previous studies have also identified gene alterations between the myxoid and RC components using clinical tumors of MLS patients. Oda et al. 43 have reported that a reduced protein expression of the cell cycle regulatory genes, p16INK and p14ARF, is more frequently observed in the RC component than in the myxoid component and may be one of the critical events during MLS progression. Furthermore, highly malignant MLS with RC components showed longer telomeres, stronger telomerase activity, and higher hTERT and c-MYC expression levels, compared with the pure myxoid variants. 44 From these studies, cell growth ability may be associated with the difference between each pathological region. Consistently with previous reports, our study shows that cell cycle-related pathways were upregulated in the RC component (Figure 4a) . However, the miR-135b overexpression did not affect cell growth in vitro (Supplementary Figure 2e) . On the other hand, the stable miR-135b-overexpressing cells exhibited enhanced tumorigenic abilities in vivo. We propose that this discrepancy was caused by the tumor microenvironment, the effect of MMP2, and the nature of the 2645-94 cells. First, the tumor microenvironment, which includes cells such as macrophages and endothelial cells as well as extracellular matrix components, proteases and cytokines, 45 has a critical role during tumor progression and metastasis. Second, a possible explanation for this discrepancy is that the increased MMP2 in the extracellular matrix as a result of THBS2 downregulation by miR-135b degrades the extracellular collagen matrixes; thus, tumor cells are likely to spread towards their surroundings. Third, the original 2645-94 cells have very weak malignancy, including tumorigenicity in vivo. These cells did not survive in nude mice (BALB/cAJcl-nu/nu), SCID mice (C. B-17/Icr-scid/scid Jcl) or NOD/SCID mice (NOD/ShiJic-scid Jcl) in our preliminary animal experiments. Therefore, it is possible that cell death is induced in some of the control cells, even if in our in vivo model using NOG mice, which may cause the differences in the tumor growth between the control and miR-135b-overexpressing cells. Our findings suggest that histopathologic differences between the myxoid and RC components may be due to the miR-135b/ THBS2/MMP2 pathway. The increased total amount of MMP2 triggers the degradation of the extracellular matrix and promotes the invasion of tumor cells in the extracellular space (Figure 7e ). We propose that this molecular mechanism, independent of cell proliferation or other mechanisms previously reported, may contribute to the morphological spectrum of MLS.
In addition, we indicated that high expression levels of miR-135b and low expression levels of THBS2 may relate to the good ability of the RC component to predict MLS patient outcomes (Figures 7b  and c) . Presently, no reliable biomarkers have been identified in sarcomas, including MLS. Although various mRNAs 46 and miRNAs 47 have been reported as disease-specific markers in sarcomas, no targeting molecules have been developed for clinical applications. Recently, it has been shown that extracellular miRNAs are contained in various bodily fluids and can circulate in the blood. 48, 49 These cellfree miRNAs could be potential diagnostic and prognostic biomarkers for various types of cancer. The expression profiles of circulating miRNAs in serum and plasma are similar to those of miRNAs derived from tumor tissues. 50, 51 Circulating miR-135b levels in the plasma of endometrial carcinoma patients have been observed to be upregulated and may serve as a novel and less invasive biomarker for diagnosis. 52 Similarly, in stool samples, the level of miR-135b is significantly higher in patients with colorectal cancer or adenomas than in non-cancerous patients. 53 There is a continued need to increase the number of available MLS tissue samples and to further investigate the expression levels of miR-135b and THBS2 in blood. Therefore, although more number of the available MLS tissue samples as well as patient-matched body fluidic samples such as blood are necessary to further investigate the possibility of miR-135b and THBS2 as biomarkers, they may be promising biomarkers reflecting the clinical outcome of MLS patients.
MATERIALS AND METHODS
Clinical samples
This study was allowed by the Institutional Review Board at the National Cancer Center (Number: 2013-102). All clinical information and materials were obtained after receiving informed consent from the patients. MLS tissue samples, including both FFPE and frozen tissue samples from MLS patients who did not receive chemotherapy or radiotherapy, were collected at the National Cancer Center Hospital of Japan between January 1997 and December 2015. For miRNA microarray analyses, we selected eight FFPE samples from MLS patients with more than 5% RC component according to pathological reports (Supplementary Table II 54, 55 and provided by Prof M Kuroda (Tokyo Medical University). The human adipose-derived stem cell line was purchased from Invitrogen (Carlsbad, CA, USA) (Lot. 1212). All cell lines were cultured in RPMI 1640 with 25 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) buffer (Life Technologies, Carlsbad, CA, USA). All media were supplemented with 10% heat-inactivated FBS (Life Technologies) and antibiotic-antimycotics (Invitrogen). The cells were maintained under 5% CO 2 in a humidified incubator at 37°C.
miRNA and mRNA microarray analysis To detect the miRNAs in the myxoid and RC components of MLS FFPE samples, 100 ng of total RNA was labeled using miRNA Complete Labeling and Hyb Kits (Agilent Technologies, Santa Clara, CA, USA) and hybridized on an Agilent SurePrint G3 Human miRNA 8x60K Rel.19 array (design ID: 046064) according to the manufacturer's protocol. Hybridization signals were scanned using a DNA microarray scanner (Agilent Technologies), and the scanned images were quantified using Agilent Feature Extraction software. We applied a ⩾ 5-fold change in signal intensity to identify significant differences in gene expression. The raw and normalized microarray data are available in the Gene Expression Omnibus database (accession number GSE73448).
To detect the mRNAs in cells derived from 2645-94 cells transfected with miR-135b mimics or NC, 100 ng of total RNA was labeled using an Agilent Low Input Quick Amp Labeling Kit, one-color (Agilent Technologies) and hybridized using Agilent SurePrint G3 Human GE v2 8x60K Microarray (Design ID: 039494) according to the manufacturer's instructions (Protocol for Use with Agilent GE Microarrays Version 6.7). Hybridization signals were scanned using a DNA microarray scanner (Agilent Technologies), and the scanned images were quantified using Agilent GeneSpring software. We applied a ⩾ 5-fold change in signal intensity to identify significant differences in gene expression. The raw and normalized microarray data are available in the Gene Expression Omnibus database (accession number GSE73347). mRNA sequencing and pathway analysis A total of 100 ng of total RNA obtained from each FFPE sample was subjected to a sequencing library construction using a TruSeq RNA Access library prep kit (Illumina, San Diego, CA USA) according to the miR-135b impacts myxoid liposarcoma progression Y Nezu et al manufacturer's protocols. The quality of the libraries was assessed with an Agilent 2200 TapeStation High Sensitivity D1000 assay (Agilent Technologies). The pooled libraries were sequenced using an Illumina HiSeq system in 101-base pair paired-end reads in rapid mode. An average of 23 M paired-end reads were yielded per sample. After trimming sequencing adaptors, low quality reads and bases with a Trimmomatic-0. 30 (ref. 56) tool, the sequence reads were aligned to a human reference genome (GRCh37/hg19) using Tophat 2.0.11 (bowtie2-2.2.1), 57 which adequately aligned the reads to the appropriate location and splice sites in the genome sequence. Files of the gene model annotations and known transcripts were downloaded from the Illumina iGenomes website (http:// support.illumina.com/sequencing/sequencing_software/igenome.html), which are necessary for the whole transcriptome alignment with Tophat. The aligned reads were subjected to successive analyses using AvadisNGS 1.6 software (Agilent Technologies). The read counts allocated for each gene and transcript (Ensembl version 2013.04.03) were quantified using a Trimmed Mean of M-value method. 58 Statistical analyses between paired groups were performed by paired t-tests. The differentially expressed genes were estimated to be significant if the fold change ⩾ 1.5.
Two hundred and six annotated human pathways were downloaded from GenMAPP (http://www.genmapp.org) and WikiPathways (http://www. wikipathways.org). The collected gene expression data were mapped to these pathways using GenMAPP 2.1. Permutation P values were calculated by MAPPFinder 2.0 to estimate statistically significant pathways having a relative amount of genes with an FC o − 2.0 (RC to myxoid).
Identification of miR-135b target mRNAs
To identify the downstream targets of miR-135b, we performed mRNA sequencing and mRNA microarray analyses as described above. We performed in silico analyses to identify potential targets of miRNA using ) were injected intramuscularlly. To detect the enhancement of tumor size and the appearance of distant metastases, mice were administered 100 mg/kg of D-luciferin (Promega, Madison, WI, USA) intraperitoneally. The signal emerging from tumor cells was visualized and quantified using the IVIS Spectrum imaging system (Caliper Life Science, Hopkinton, MA, USA). Tumor development was monitored once a week. At 3 and 10 weeks after cell injection, tumors and lungs were extracted from the 2645-94 GFP-Luc LM2 and 2645-94 GFP-Luc mice, respectively. The tumor volumes were estimated by the formula V = a 2 × b/2, where a and b are the short and long tumor axes, respectively. The cellular density of primary tumor and the number of lung-metastatic foci were evaluated by microscopy. The area of primary site and the focus size were measured by BZ-X analyzer software (Keyence, Osaka, Japan). To establish a high lungmetastatic cell line, the 2645-94 GFP-Luc LM2 cell line, consecutive in vivo lung metastasis selections were performed twice using the 2645-94 GFP-Luc cell line.
Statistics
The data presented in bar graphs are the mean ± s.e.m. of at least three independent experiments. The statistical analyses were conducted using Student's t test (direct comparison), Dunnett's test (multiple comparison) and Fisher's exact test. We performed receiver-operating characteristic curve analyses using SPSS Statistics Version 21 software (IBM SPSS, Armonk, NY, USA). The optimal cutoff points for the expression levels of miR-135b and THBS2 were determined by the Youden index. The KaplanMeier method and the log-rank test were used to compare patient survival. We defined the survival period as the time from diagnosis until recurrence or metastasis, whereas living patients were censored at the time of their last follow-up. P valueso 0.05 were considered significant.
